Protein synthesis inhibition

Protein synthesis inhibition refers to the blockage of protein biosynthesis within cells via interruption of ribosome-driven mRNA translation. This mechanism is exploited therapeutically in antimicrobial drugs and anticancer agents to arrest cell growth and induce cell death. Most clinically relevant compounds target the ribosome—a complex macromolecular machine with distinct structural differences between prokaryotes and eukaryotes, allowing for selective toxicity toward bacterial cells. Drugs may act at different stages (initiation, elongation, termination) and affect diverse functional sites, including tRNA entry, peptidyl transferase activity, and ribosome binding/assembly. Protein synthesis inhibition is a functional therapeutic strategy rather than a specific molecular entity and should not be confused with discrete targets such as “30S ribosomal subunit” or “peptidyl transferase”

Other names

Inhibition of protein synthesisAntibiotic action on ribosomeTranslation inhibitionProtein translation inhibition

Inhibition of ribosome function (initiation, elongation, or termination phases); Blocking aminoacyl tRNA entry; Inhibition of peptidyl transferase activity; Interference with ribosomal assembly; Mistranslation induction; Inhibition of ribosome recycling or termination.